Performance Measurement Network

Question: Pradaxa (dabigatran) prescribed at discharge

This question has follow-up question(s): what if Pradaxa (dabigatran) is prescribed at discharge?

A patient was prescribed Pradaxa at discharge. Pradaxa is an anticoagulant, thrombin inhibitor but not listed in Tables 8.2 Antithrombotic Medications for Stroke or 8.3 Anticoagulant Medications for Stroke. Can it be abstracted as antithrombotic / anticoagulant therapy prescribed at discharge?


Pradaxa/dabigatran will be added to Appendix C, Medication Tables 8.2 and 8.3 with the next revision of the specifications manual (Version 3.4); however, version 3.4 will not become effective until Jan. 1, 2012. Pradaxa was approved by the FDA on October 19, 2010 as a new anticoagulant for the prevention of stroke in patients with atrial fibrillation. Select 'Yes' for both Antithrombotic and Anticoagulant Therapy Prescribed at Discharge if Pradaxa is prescribed at discharge.

Question Details
Focus area(s): Chart Abstracted Measure Specifications – Clinical
Related documents: STK-02,

Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Performance Measurement Network? Send feedback
This website is using cookies. More info. That's Fine